TSE:6378
TSE:6378Machinery

Asian Dividend Stocks To Enhance Your Portfolio

As global markets exhibit mixed signals, with Japan facing monetary tightening and China experiencing an economic slowdown, investors are increasingly turning their attention to dividend stocks in Asia as a potential source of steady income amidst uncertainty. In such a dynamic environment, selecting dividend stocks that offer stable yields and have resilient business models can be crucial for enhancing portfolio performance.
TSE:3994
TSE:3994Software

Assessing Money Forward (TSE:3994) Valuation After Governance Shake-Up and Board Restructuring Plans

Money Forward (TSE:3994) just unveiled a governance reshuffle, with several long serving external directors set to retire under newly formalized term limit and age rules, alongside a fresh review of its management structure. See our latest analysis for Money Forward. The governance clean up comes after a tough stretch for investors, with the share price down sharply over the last quarter and a weaker one year total shareholder return signaling that momentum has been fading. Still, today's...
TSE:6856
TSE:6856Electronic

Evaluating HORIBA (TSE:6856)’s Valuation After Its Strong Recent Share Price Momentum

HORIBA (TSE:6856) has been quietly building momentum, with the share price up around 16% over the past month and more than 80% over the past year. This has drawn fresh attention to its valuation. See our latest analysis for HORIBA. With the share price now around ¥15,980, HORIBA’s strong 30 day and year to date share price returns, alongside an impressive multi year total shareholder return, point to clear positive momentum as investors reassess its growth and risk profile. If HORIBA’s run...
TSE:4506
TSE:4506Pharmaceuticals

Hematology Pipeline Advances Could Be A Game Changer For Sumitomo Pharma (TSE:4506)

In December 2025, Sumitomo Pharma America presented updated Phase 1/2 clinical data at the 67th American Society of Hematology Annual Meeting in Orlando, highlighting its investigational oral menin inhibitor enzomenib for relapsed or refractory acute leukemia and PIM1 kinase inhibitor nuvisertib for relapsed or refractory myelofibrosis. The promising response rates and favorable safety profiles reported for these two early-stage oncology candidates point to a strengthening hematology...